Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD

Executive Summary

Indian firms must transition from “plain-vanilla” generics to more complex products, including biosimilars, if they want to continue growing. However, returns from the sector’s so-called Third Wave will be some time coming, warns Lupin’s managing director Nilesh Gupta.

You may also be interested in...



Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure

Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.

Japan Price Reforms Will Be Pro-Innovation, Inclusive - Official

A Japanese official provides reassurances at BIO Asia that the government intends to abide by drug pricing policies that support innovation, although the research-based pharma industry remains concerned that sweeping reforms now under discussion may hamper R&D and investment in the country.

Big Pharma Restructures Commercial Teams In India

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel